胸腺肽α1联合门静脉肝动脉灌注化疗对肝癌术后免疫功能及远期疗效的影响

摘要

目的：观察胸腺肽α1联合门静脉肝动脉灌注化疗对肝癌术后免疫功能及远期疗效的影响。方法选择2012年4月至2014年4月医院收治的肝癌患者140例，根据治疗方法不同分为观察组和对照组，各70例。对照组患者接受门静脉肝动脉灌注化疗，观察组患者在对照组基础上接受胸腺肽α1治疗。结果观察组Th1细胞因子肿瘤坏死因子α（TNF－α），干扰素γ（IFN－γ）含量分别为（61.86±9.52) ng/L和(55.28±6.35）ng/L，免疫球蛋白IgA，IgG，IgM分别为（15.17±2.13) g/L，(2.89±0.34) g/L，(1.62±0.21）g/L，以及补体C3和C4分别为（1.42±0.21) g/L和(0.39±0.06）g/L，明显高于对照组（ P<0.05）；而观察组Th2细胞因子白细胞介素（IL－6）和白细胞介素（IL－10）含量分别为（66.81±3.91)μg/L和(25.24±3.24）μg/L明显低于对照组（ P<0.05）；治疗后6个月、1年、2年时，观察组患者的存活率分别为91.43%，82.86%，74.29%，均明显高于对照组（ P<0.05）。结论胸腺肽α1联合门静脉肝动脉灌注化疗有助于改善患者的免疫功能，提高远期存活率。%Objective To study the influence of thymosin α1 combined with the portal vein and hepatic artery infusion chemotherapy on postoperative immune function and long-term curative effect of liver cancer. Methods 140 cases of liver cancer in our hospital from April 2012 to April 2014 were divided into the observation group and the control group according to the different therapies, 70 cases in each group. The control group received the portal vein and hepatic artery infusion chemotherapy, while on this basis the observation group received the thymosin α1 treatment. Results The Th1 cytokine TNF-α and IFN-γ contents in the observation group were ( 61. 86 ± 9. 52 ) , ( 55. 28 ± 6. 35 ) ng/L respectively, the immunoglobulin IgA, IgG and IgM levels were ( 15. 17 ± 2. 13 ) , ( 2. 89 ± 0. 34 ) , ( 1. 62 ± 0. 21 ) g/L and the complement C3 and C4 contents were ( 1. 42 ± 0. 21 ) , ( 0. 39 ± 0. 06 ) g/L, which were significantly higher than those in the control group with statistical differences ( P<0. 05 ) . The Th2 cytokine IL-6 and IL-10 contents in the observation group were ( 66. 81 ± 3. 91 ) , ( 25. 24 ± 3. 24 )μg/L, which were significantly lower than those in the control group with statistical differences ( P < 0. 05 ); the survival rates at 6 month, 1 year, 2 years after treatment in the observation group were 91. 43% , 82. 86% and 74. 29% respectively, which were significantly higher than those in the control group with statistical differences ( P<0. 05 ) . Conclusion Thymosin α1 combined with the portal vein and hepatic artery infusion chemotherapy is helpful to improve the immunity function and increase the long-term survival rate.